FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2022
Top Tier Clinicians and Researchers Find the Tests Are:
-Full of Revolutionary Potential
-Valuable Now For Research and Treatment Trials
-Not Ready Yet for the Healthcare Provider’s Office
CHICAGO and SAN DIEGO, July 31, 2022 /PRNewswire/ — Alzheimer’s disease blood biomarkers (BBMs) may revolutionize the diagnosis of Alzheimer’s in the future, but are not yet ready for widespread use, according to a newly-published article by leading international clinicians and researchers convened by the Alzheimer’s Association®. At the same time, they are important and valuable for current research trials and cautious initial use in specialized memory clinics.
“Blood-based markers show promise for improving, and possibly even redefining, the diagnostic work-up for Alzheimer’s,” said Maria C. CarrilloPh.D., Alzheimer’s Association chief science officer and a co-author of the article. “Remarkable progress has been made, but additional data are needed before BBMs can be used as a stand-alone test for diagnosis, and before considering broad use in primary care settings.”
“In this article, the expert workgroup clearly defines both short- and long-term research priorities needed to fill significant knowledge gaps that still exist, such as how well these blood-based markers work in diverse communities and in those living with multiple health conditions ,” Carrillo added. “Also included are consensus appropriate use recommendations for use of BBMs in the clinic and in research trials.”
“The Alzheimer’s Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer’s Disease,” by Oskar HanssonMD, Ph.D., et al, is published online today by Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The recommendations will be reported today and tomorrow at the Alzheimer’s Association International Conference® (AAIC®) 2022 in San Diego and online.
“Blood-based biomarkers for Alzheimer’s are already improving the design of clinical trials, and they are very likely to revolutionize the diagnosis of Alzheimer’s in the future,” said Oskar HanssonMD, Ph.D., director of the Center for Neurodegenerative Diseases at Lund University and Skane University Hospital, Malmo, Swedenand first author on the newly published article. “That said, the implementation of such markers in trials and practice must be done in a careful and controlled way so as not to accidentally cause more harm than good. Much more research is needed before widespread clinical use of BBMs.”
According to the article, BBMs show “great …